公开(公告)号：US20240011066A1

公开(公告)日：2024-01-11

申请号：US18303451

申请日：2023-04-19

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Shahram Misaghi ,  Amy Shen ,  Inn Huam Yuk ,  Gavin Christian Barnard ,  Simon Auslaender ,  Niels Bauer ,  Benedikt Oswald

IPC: C12P21/02 ,  C12N15/90 ,  C12N15/11 ,  C12N9/00 ,  C12N9/22 ,  C12N9/10 ,  C12N9/86

CPC classification number: C12P21/02 ,  C12N15/907 ,  C12N15/11 ,  C12N9/93 ,  C12N9/22 ,  C12N9/1029 ,  C12Y203/01 ,  C12N9/86 ,  C12Y305/02006 ,  C12N2310/20 ,  C12N2800/80

Abstract: Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.

公开(公告)号：US20240409615A1

公开(公告)日：2024-12-12

申请号：US18752501

申请日：2024-06-24

Applicant: Genentech, Inc.

Inventor： Chi Kin Domingos Ng ,  Amy Shen ,  Gavin Christian Barnard

IPC: C07K16/00 ,  C12N15/85

Abstract: The presently disclosed subject matter relates to multi-vector recombinase mediated cassette exchange approaches to achieve targeted integration of sequences of interest for the generation host cells expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes, and other difficult to express molecules.

公开(公告)号：US20240254199A1

公开(公告)日：2024-08-01

申请号：US18489274

申请日：2023-10-18

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Amy Shen ,  Inn Huam Yuk ,  Gavin Christian Barnard ,  Shahram Misaghi ,  Simon Auslaender ,  Niels Bauer ,  Benedikt Oswald

IPC: C07K16/00 ,  C12N5/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12P21/00

CPC classification number: C07K16/00 ,  C12N5/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12P21/00 ,  C12N2310/20 ,  C12N2800/80

Abstract: The present disclosure relates to mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells) that are modified to reduce or eliminate the expression of certain mammalian cell endogenous products (e.g., host cell proteins and virus-like particles), and methods of using such cells in the production of a recombinant product of interest, e.g., a recombinant protein, a recombinant viral particle, or a recombinant viral vector. These modifications were specifically chosen to generate engineered mammalian host cells with desired traits in several key areas, including improved cell culture performance (e.g., higher viability and product titers), improved product quality (e.g., more consistent and favorable glycosylation; more stable drug product), and decreased burden on purification for removing problematic or undesired endogenous host cell products (e.g., hydrolytic host cell proteins and virus-like particles) during biomanufacturing.

公开(公告)号：US20240240156A1

公开(公告)日：2024-07-18

申请号：US18510297

申请日：2023-11-15

Applicant: Genentech, Inc.

Inventor： Amy Shen ,  Gavin Christian Barnard ,  Shuet Ming Yip

IPC: C12N5/071 ,  C07K16/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/85

CPC classification number: C12N5/0682 ,  C07K16/00 ,  C12N9/22 ,  C12N15/111 ,  C12N15/85 ,  C07K2317/622 ,  C12N2310/20 ,  C12N2840/002

Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins where the TI host cells are also subjected to transposon-mediated genomic integration of one or more exogenous nucleic acids, as well as methods of producing and using said combined transposon-mediated genomic integration and TI host cells.